Lonza Group restates 2025 half-year figures, shares react on SIX trade
23.06.2026 - 14:57:31 | ad-hoc-news.de
By Christina Vogel, Background & Management desk. Reviewed prior to publication on 2026-06-23, 14:56.
Lonza Group AG (CH0013841017) has restated its half-year 2025 financials to present the Capsules & Health Ingredients business as discontinued operations, as disclosed in an ad hoc announcement on SIX Swiss Exchange dated 23 June 2026. The move precedes the scheduled half-year 2026 results release on 22 July and comes as Lonza shares remain a heavyweight in the Swiss mid-cap SMIM index.
What the restatement changes
In its Art. 53 LR ad hoc statement, Lonza explains that the half-year 2025 figures have been recast so that Capsules & Health Ingredients (CHI) is reported under discontinued operations, aligning the interim accounts with the full-year 2025 presentation following the divestment decision in December 2024. The company states that the restatement covers the consolidated income statement, selected key performance measures and related notes, while leaving the previously reported full-year 2025 numbers unchanged, according to the official Lonza investor communication.
The ad hoc release also recalls that Lonza entered into a definitive agreement on 6 March 2026 to sell the CHI business to Lone Star Funds, with closing expected in the third quarter of 2026, subject to customary conditions. This transaction is part of Lonza's tighter focus on contract development and manufacturing services, which positions the group alongside global CDMO peers such as Catalent and Thermo Fisher Scientific in investor sector comparisons, as highlighted by a Reuters morning brief on Swiss shares.
CDMO focus and upcoming earnings
With CHI classified as discontinued, Lonza's continuing operations now reflect primarily its biologics, cell and gene, and small molecules CDMO activities, which generated the bulk of EBITDA in recent reporting periods, according to previous company filings. The restated half-year 2025 financials are intended to provide investors with a cleaner comparison base ahead of the half-year 2026 report on 22 July 2026, where the company will update on demand trends in biologics manufacturing and capacity utilization across its sites, per the structured guidance in the Financial Times summary of the ad hoc release.
Market data from platforms tracking the SIX Swiss Exchange show that Lonza shares recently traded around the mid-530s Swiss francs, implying a market capitalization in the low-40-billion Swiss franc range and placing the group among the larger life sciences tools and services names in Europe. On MarketScreener, the stock is classified in the biotechnology and life sciences tools segment, with a recent indicative price of about 508.60 Swiss francs at 10:56 local time and a modest negative performance since the start of the year, according to the MarketScreener profile on Lonza.
All news and analysis on the Lonza Group shares
Further company announcements, analyst views and price data on Lonza Group can be found in the dedicated topic section and via the company’s investor relations pages.
The product engine behind Lonza
Lonza generates revenue by providing contract development and manufacturing services for pharmaceuticals and biologics, with key offerings including mammalian cell culture manufacturing for monoclonal antibodies and advanced therapies. A representative product line is its biologics CDMO services, which cover process development, clinical supply and large-scale commercial manufacturing for biotech and pharmaceutical clients worldwide.
Where the Lonza shares trade today
The Lonza Group AG shares (CH0013841017) most recently traded on SIX Swiss Exchange at 538.00 Swiss francs as of 2026-06-23, 09:30.
Lonza Group in figures
- Company: Lonza Group AG
- ISIN: CH0013841017
- WKN: 928619
- Ticker: LONN
- Trading venue: SIX Swiss Exchange
- Price (as of 2026-06-23, 09:30): 538.00 CHF
- Market cap: 40.5 billion CHF (as of 2026-06-23)
- Sector / industry: Healthcare - Life Sciences Tools & Services / CDMO
- Index membership: SPI, SMIM
- Next earnings date: 2026-07-22
This article is for informational purposes only and does not constitute investment advice, an offer, or a solicitation to buy or sell any securities. Investors should conduct their own research or consult a qualified financial advisor before making investment decisions.
